We review the evidence implicating a strong association between chronic inflammation and cancer, with an emphasis on colorectal and lung cancer.
Several high-risk forms of human papillomavirus (HPV) antibodies may be associated with an increased risk of lung cancer, according to research presented at the annual meeting of the American Association for Cancer Research, held April 2 to 6 in Orlando, Fla.
The review by Jan Buter and
Giuseppe Giaccone in this issue
of ONCOLOGY is an excellent
overview of the current status
of the anti–epidermal growth factor
receptor (EGFR) agents gefitinib (Iressa),
erlotinib (Tarceva), and cetuximab
(Erbitux). The authors address
some of the most important issues
regarding anti-EGFR agents currently in clinical development. Key among
these are the importance of patient
selection and drug dosage in the success
and failure of various clinical
trials. This article raises several very
interesting questions in the development
of this class of agents.